Spinal muscular atrophy (SMA) is the most common genetically inherited neurodegenerative disease that leads to infant mortality worldwide. SMA is caused by genetic deletion or mutation in the survival of motor neuron 1 (SMN1) gene, which results in a deficiency in SMN protein. For reasons that are still unclear, SMN protein deficiency predominantly affects α-motor neurons, resulting in their degeneration and subsequent paralysis of limb and trunk muscles, progressing to death in severe cases. Emerging evidence suggests that SMN protein deficiency also affects the heart, autonomic nervous system, skeletal muscle, liver, pancreas and perhaps many other organs. Currently, there is no cure for SMA. Patient treatment includes respiratory care, physiotherapy, and nutritional management, which can somewhat ameliorate disease symptoms and increase life span. Fortunately, several novel therapies have advanced to human clinical trials. However, data from studies in animal models of SMA indicate that the greatest therapeutic benefit is achieved through initiating treatment as early as possible, before widespread loss of motor neurons has occurred. In this review, we discuss the merit of carrier and perinatal patient screening for SMA considering the efficacy of emerging therapeutics and the physical, emotional and financial burden of the disease on affected families and society.
Introduction
Spinal muscular atrophy (SMA) is an autosomal recessive disease, which affects approximately 1 in 10,000 live births and has a carrier frequency of 1 in 40 people [1] [2] [3] . The hallmark of the disease is degenerative loss of α-motor neurons in the brain stem and spinal cord leading to progressive weakness of bulbar, trunk and limb muscles, and eventually paralysis in severe forms of the disease [3] [4] [5] . Thoracic cage deformation and respiratory muscle weakness can lead to respiratory failure, which frequently results in death, particularly in early onset cases which are typically more severe [6] . SMA causes the death of more infants than any other genetic disorder and is currently incurable [1, 4] . Appropriately, this disease is the focus of numerous disease pathology and therapeutic research laboratories all over the world.
SMA genetics and disease severity

Genetic basis of SMA
SMA is caused by deletion or mutation of the survival of motor neuron 1 (SMN1) gene found on chromosome 5q in band 13 [7, 8] . Homozygous deletion of SMN1 occurs in approximately 95% of patients with SMA 5q13 [8] , with the remainder displaying a heterozygous state in which one SMN1 allele is deleted and the other contains a non-synonymous mutation, or more rarely two SMN1 alleles that both contain intragenic mutations [9] . The functional loss of SMN1 results in a deficiency of SMN protein; however the protein is not completely absent in affected patients due to the presence of SMN2, a second SMN gene also present on 5q13 [7] . The SMN2 gene differs from SMN1 by five nucleotides [7] , but only one of these point mutations occurs in a coding region: the cytosine found at position +6 of exon 7 in SMN1 is a thymidine in SMN2 [10] . Although this is a silent transition in terms of the amino acid encoded, the change to thymidine at this position results in a dramatic alteration in pre-mRNA splicing, such that exon 7 is excluded from~90% of SMN2 mature transcripts [11] . The protein generated from this alternatively spliced transcript, termed SMNΔ7, is unable to fulfill the functional roles of fulllength SMN protein. A relatively small amount of full-length SMN protein is generated from the 10% of SMN2 transcripts that include exon 7 [11] . No patients have been identified who have deletions or functional loss of both SMN1 and SMN2 [7] , suggesting that loss of both genes results in embryonic lethality [12, 13] . Mice encode only one Smn gene, and homozygous deletion of this gene is embryonic lethal [12] . In the absence of SMN1, the full-length SMN protein generated from SMN2 is sufficient to prevent embryonic lethality but not sufficient to prevent the degeneration of α-motor neurons and the subsequent presentation of SMA. In general, disease severity is inversely correlated with the copy number of SMN2 [14, 15] .
Multiple hypotheses exist regarding the mechanism by which the cytosine to thymidine change at position +6 of exon 7 causes its exclusion from the final transcript. Because this exon features weak splicing sites at both the 3′ and 5′ ends [16] , proper inclusion of the exon is dependent on cis elements -DNA regions which are recognized by trans-acting splicing proteins and thereby enhance the inclusion or exclusion of a given element in a transcript. These elements include intronic splicing enhancers (ISEs), intronic splicing silencers (ISSs), exonic splicing enhancers (ESEs), and exonic splicing silencers (ESSs). At least one cis element from each category is believed to be involved in splicing of exon 7 in SMN2 [17] [18] [19] [20] [21] [22] [23] [24] [25] . Thus, one therapeutic approach currently under development is targeting these various elements to enhance the probability of inclusion of exon 7 in pre-mRNA derived from SMN2 (discussed below).
Variable severity and disease types
Patients with SMA are categorized into one of five types, depending on age of disease onset, peak motor function achieved, and life expectancy (Table 1) [28] . However, it is generally recognized that SMA presents as more of a continuum of phenotypes rather than discrete types [29] . Type 0 is characterized by congenital onset, respiratory distress at birth, and very low life expectancy. This type of SMA is generally immediately fatal if the patient does not receive respirator support at birth. Type 1, known as WerdnigHoffmann disease, presents before six months of age. Patients with type 1 SMA are unable to sit independently and life expectancy is less than two years [30] . In type 2, onset typically occurs between 6 and 18 months of age. These patients are able to sit independently but never achieve the ability to walk, and have life expectancies between 10 and 40 years. Patients with type 3, known as Kugelberg-Welander disease, experience disease onset after 18 months and ultimately achieve the ability to walk. Patients with type 4 SMA typically present as adults, exhibit wide phenotypic variability, and retain the ability to walk [31] . Types 3 and 4 are not usually associated with a reduced life expectancy [26] . For a historical perspective on the early identification of SMA, please see Reference [32] .
Several groups have performed detailed observational studies on disease progression in patients with SMA types 1, 2 and 3 [33] [34] [35] [36] [37] . Natural history studies provide much needed information on the course of disease progression, which can aid in assigning appropriate clinical outcome measures in human trials of novel investigational approaches to SMA treatment or management. In general, the highest motor function achieved by a patient with SMA is more highly correlated to prognosis than age of onset [33] . Among patients with similar ages of onset, those who achieved the ability to sit or to walk independently lived longer than those who did not [33] .
SMA type and prognosis are generally inversely correlated to the number of copies of the SMN2 gene, an important modifier of disease severity [14, 15, 38] . The SMN locus is variably amplified and, in patients with increased SMN2 copy number, an additive effect occurs in which the combined fulllength transcript derived from each copy of the gene brings the patient closer to the levels of SMN present in an unaffected person. Quantitative PCR analysis performed by Feldkötter et al. determined the SMN2 copy number of 375 patients with SMA of known type [27] . From these data, the authors generated percentage ratios that approximate the likelihood of each SMA subtype when the SMN2 copy number is known (Table 1) [27] . For example, the likelihood of an affected child with only one copy of SMN2 acquiring type 1 SMA is greater than 99.9%. With two copies of the gene, the probability of type 1 SMA is 97.26%, while the probabilities of type 2 and type 3 are 2.7% and 0.04%, respectively. With 3 or 4 copies of the SMN2 gene, the patient is most likely to have type 2 and type 3 SMA, respectively (note: this study was not designed to detect more than 4 copies of SMN2). However, this study suggests that [40] [41] [42] , which further confounds a prediction of disease severity based solely on SMN2 copy number (of note, the role of PLS3 as a modifier of SMA disease severity has not been supported in some mouse models of SMA [43] ). Thus, clinical assessment of peak motor function still provides one of the best predictors of disease severity and life expectancy.
SMN protein, putative functions and cell types affected
The SMN protein is 38 kDa in size, is ubiquitously expressed, and is found in both the cytoplasm and the nucleus [44, 45] . Full-length SMN protein self-oligomerizes via association of a 30-amino acid domain encoded by exon 6, and missense mutations within or immediately adjacent to this domain inhibit the ability of the protein to self-associate [46] . The SMNΔ7 protein produced from the SMN2 gene shows a greatly reduced ability to self-associate [46] . Following self-oligomerization, nuclear SMN is recruited into a macromolecular complex containing Gemin proteins. The formation of this complex appears to have a stabilizing effect on the SMN protein, and failure to self-oligomerize or to be recruited into these complexes may in part explain the reduced half-life of SMNΔ7 protein compared to the full-length protein [47] . The SMN complex is composed of SMN and Gemins 2 through 8 [48] , and is found in subnuclear structures known as gems. The name is derived from Gemini, as the nuclear structures resembled twins of other previously identified coiled bodies in the nucleus [44] . The cellular localization of the complex appears to be influenced by its interaction with unrinteracting protein (Unrip), which directs localization to the cytoplasm and is absent in nuclear gems [49] . SMN appears to have many different functions, including roles in small nuclear ribonucleoprotein (snRNP) assembly and pre-mRNA splicing [50] , translational regulation [51] , R-loop resolution [52] , transport of β-actin mRNA and secretion vesicles [53, 54] , and regulation of actin dynamics [55, 56] (Table 2) .
Although there is accumulating evidence that SMA is more than simply a disease of motor neurons, most studies in mouse models of SMA have focused on the effect of reduced levels of SMN on motor neuron function. These effects include altered splicing of many genes [50, [72] [73] [74] , poor terminal arborization [58] , aggregation of neurofilaments in the motor end plate [58] , impaired synaptic vesicle release [75] , reduced neuromuscular junction plasticity [76] and, ultimately, denervation and death of the motor neuron [77] . All of these defects occur very early during disease progression, indicating that abnormal motor neuron structure and function are an early hallmark of the disease.
Although α-motor neurons are most affected in SMA, recent studies have shown that other tissues are also affected [78] ( Table 2 ). Reduced levels of SMN in pre-symptomatic mice are associated with muscle weakness, and a delay in the appearance of mature isoforms of proteins important for muscle contractions [63] . Low levels of SMN cause muscle satellite cell defects, which manifests as the aberrant initiation of the differentiation program and reduced efficiency of myotube formation [62, 63, 79, 80] . Similar observations were found in studies with myoblasts from patient with SMA [81] . Several studies have described cardiac muscle defects in mouse models of SMA [67] [68] [69] , which are also observed in severe human disease [82] . Recently, defects in glucose metabolism and pancreatic function have been detected in SMA mice [64] . Indeed, heterozygous Smn +/− mice (mice naturally only have one copy of the Smn gene [12] ) display defects in pancreas development and aberrant glucose metabolism, in the absence of any SMA-like disease, suggesting SMN may represent a diabetes susceptibility locus [65, 83] . A recent study showed that reduced levels of SMN impact the ability of astrocytes to perform their normal functions of supporting neuron development and synapse formation [59] . Astrogliosis is Cardiac defects and bradycardia [67] [68] [69] ; vasodilation defects [70, 71] evident in end-stage SMA mice and in post-mortem patient spinal cords, and restoration of SMN specifically in astrocytes of SMA mice increased lifespan, improved motor unit function, and normalized neuromuscular junction defects. Intrinsic defects were also observed in Schwann cells deficient in SMN, which included reduced ability to myelinate neurons [60] . However, although restoration of SMN exclusively in Schwann cells did reverse the myelination defects in a mouse model of SMA, motor neuron survival was not improved [84] . Taken together, these studies demonstrate that although SMA may be considered primarily a disease of α-motor neurons, there are deficiencies that arise in other types of neurons, muscle, liver and pancreas that may contribute to the disease state. Since patients with SMA are now living longer due to improved assistive technology, these recently identified "secondary" deficiencies need to be more closely examined to evaluate their impact on the clinical course of SMA. Furthermore, truly effective therapies may need to restore SMN levels body-wide to achieve a complete beneficial effect.
Emerging therapies for SMA and the therapeutic window
Given the prevalence and potential severity of SMA, numerous research groups are working to identify novel therapies for this devastating disease (for review, please see References [78, 85, 86] ). There are three broad areas to which therapies can be directed, including (1) correct the aberrant splicing of the SMN2 gene product or stabilize the SMNΔ7 protein; (2) target the downstream damage caused by SMN deficiency by protecting affected tissues from death; or (3) reintroduce the missing SMN1 gene or its gene product using a therapeutic vector. Within each of these strategies, there exists a wide variety of therapeutics in development (Table 3) , some of which have entered clinical trials. For example, an antisense oligonucleotide therapeutic developed by IONIS Pharmaceuticals (formerly ISIS Pharmaceuticals) and Biogen Idec designed to block splicing-out of exon 7 from the SMN2 transcript, has completed a phase I clinical trial in 28 patients [87, 88] . The agent was well tolerated and appeared to improve motor function in some of the treated patients. In the follow-up open-label Phase II study of children with SMA, IONIS observed a time-and dose-dependent increase in muscle function scores in children treated with multiple-doses of their lead oligonucleotide ISIS-SMNRx or nusinersen [89] . No severe adverse events were reported. Nusinersen efficacy is currently being assessed in a Phase III clinical trial [90] . A self-complementary adeno-associated viral vector based on serotype 9 (sc-AAV9) encoding a full-length copy of the SMN1 cDNA, which showed very promising results in mouse models of SMA [91] , is currently in Phase I/II clinical trial in children with SMA Type I [92] . Preliminary results from this study showed that the vector, AVXS-101, appears to be generally safe and well tolerated in the nine patients studied to date, and all patients experienced an improvement in motor function [93] . Thus, at least two therapies are showing promise in clinical trials for SMA.
A central theme that has emerged from preclinical studies of novel therapies in SMA mice is the importance of early intervention to achieve maximal therapeutic benefit. Antisense oligonucleotides that rescue the phenotype in SMA model mice must be administered in utero or immediately upon birth to achieve the greatest beneficial effect [66, 94, 95] . Similarly, studies utilizing the scAAV9-SMN1 showed that the vector had to be delivered very soon after birth of the affected mice in order to achieve a therapeutic benefit and extend mouse survival [91] . The therapeutic window for severe SMA in human patients is believed to be early and narrow, to prevent the rapid degeneration of the α-motor neurons and other affected tissues. Therefore, early detection is essential to identify candidates for the many therapeutics currently approaching or entering the clinic [3, 96, 97] . 
Genetic screening for SMA: cost versus benefit
Genetic testing and carrier screening
Considering the brevity of the therapeutic window for patients with the most severe form of SMA, early detection of SMA will likely be essential to the success of any therapeutic regimen. Although the merit of universal prenatal/neonatal screening for SMA is currently being debated, carrier screening is presently performed for parents of an affected child in an attempt to predict the risk of recurrence in future children [98] . In addition to confirming their carrier status, parents of an affected child are assessed for their SMN2 copy number in an effort to predict the severity of SMA and prognosis in a potentially affected child, although, as discussed above, there is an imperfect correlation between SMN2 copy number and disease prognosis.
There are a number of methods available to screen DNA for SMN1 deletion or SMN2 copy number (for an overview, please see Reference [97] ). Perhaps the most suitable screening method among current technologies for hospital-based testing is PCR/restriction enzyme digestion analysis. This method allows for unambiguous detection of SMN1 deletion [99] , however, the method does not detect point mutations resulting in functional loss of SMN1, and therefore additional diagnostic tests are necessary when the carriers exhibit such mutations. An emerging technology, which identifies SMN1 point mutations and gene dosage of SMN2, is high resolution melting analysis (HRMA) [100] . HRMA analysis is relatively quick, and amenable to high throughput capabilities, which makes this assay perhaps best suited for population-based screening. New techniques such as whole exome or whole genome sequencing are fundamentally changing the way novel disease-causing genes are identified and patients diagnosed [101] , and it is likely that in the future these technologies will impact diagnosis of SMA. However, currently these techniques are ineffective at distinguishing SMN1 from SMN2 or SMN2 copy number.
The debate over population-based screening for SMA
There is debate regarding the utility of genetic screening for SMA primarily due to the limitations of carrier screening and the incurable status of the disease. Opponents of population-based SMA screening cite the significant costs of widespread screening [102] , the potential for false negatives in carrier testing [96] , and the concern that carrier status testing is only relevant for couples preparing to conceive a child together. SMA carrier status does not affect the health of the individual, and knowing that one is a carrier might affect the decision to have children. The prospect of widespread screening is also given pause by the absence of a cure for the disease. Screening for SMN violates the second of ten criteria adopted by the World Health Organization (WHO) in 1968 (the Wilson-Jungner criteria), which states that in order for a genetic screen to be warranted, "there should be an accepted treatment for patients with recognized disease" [103] . The American Congress of Obstetricians and Gynecologists (ACOG) cautions against such screening particularly in the prenatal case, as improper understanding of the variability in disease phenotype may lead to poorly informed terminations of pregnancy [104] .
Several groups have argued in favor of population-based carrier screening. Due to the high carrier frequency and clinical severity of the disease, the American College of Medical Genetics (ACMG) recommends population-based SMA carrier screening in addition to screening of all members of an affected family [2] . The Muscular Dystrophy Association (MDA) has advocated that genetic diseases for which new therapeutics are entering clinical study, such as SMA, ought to be granted priority in the review process used to determine which diseases merit widespread newborn screening [105] . While it is true that no accepted treatment for SMA currently exists, early detection of SMA by a prenatal/neonatal screen could improve quality of life for the patient by allowing the parents to anticipate immediate health needs and prepare for the proper medical care of the affected child [106] .
A recent reassessment of the Wilson-Jungner criteria published by the WHO recognized the benefits of genetic screening for disease which lack an accepted treatment, and a new set of tentative criteria was generated based on this consideration and on other new developments in genomics [107] . This new set of criteria does not require a specific established treatment for a disease, but instead requires an established need for the screen, a clear target population, and the integration of patient education in the screening program, none of which is an obstacle to SMA screening [107] . Considering these more modern ethical criteria and the current state of screening technology, widespread screening for SMA certainly warrants further discussion.
Financial cost of SMA
Cost of illness (also referred to as burden of disease) refers to the financial burden incurred by the patient, the patient's family, and insurance companies to fund treatment of the disease and non-medical accommodations related to the illness. A recent study by the Lewin group, funded by the MDA, evaluated the annual cost of illness of several muscular disorders including hereditary progressive muscular dystrophy (HPMD), myotonic dystrophy (MMD), congenital muscular dystrophy (CMD), amyotrophic lateral sclerosis (ALS), and SMA [108, 109] . Patients with SMA were not separated by disease type, but instead were divided into patients whose disease onset occurred prior to three years of age (SMA Early Onset) or later (SMA Other). The mean medical expenditure for privately insured patients in the SMA Early Onset category was $121,682 USD annually (all numbers are given in US dollars), substantially higher than the means for the other diseases (CMD was second highest with $32,341). However, the sample size for the SMA Early Onset category was small and there was considerable variability between patients (standard error = $98,898, n = 14). Since many patients who experience early onset of SMA exhibit type 1 disease, the severity of the disease and the acute medical attention required for these patients may account for such high medical expenses. Mean annual medical costs for patients in the SMA Other category were lower ($20,085, standard error = $1,811), but similar to the other muscular diseases [108, 109] .
In addition to funds spent on direct medical diagnosis and treatment, patients with SMA and their families may incur non-medical expenses, such as wage loss, caregiver salaries and cost of assistive devices to enhance the patient's mobility and independence. An important cost to consider is wages lost by the patient or the patient's family, particularly for the SMA Early Onset group, in which 81.45% of patients required 16 or more hours of attendance per day [108, 109] . The estimated annual loss of income for parents and guardians of patients with early-onset SMA, with a weighted average which considers wages lost and the time cost for sustained attendance of the patient, is $35,623 (standard error = $2462), considerably higher than the second highest wage loss ($19,217 for ALS). The higher level of mobility associated with later onset of SMA is expected to cause the lower wage loss in the SMA Other group, with a mean loss of $11,110 (standard error = $627). The authors reported the mean annual cost for other nonmedical expenditures, including home modifications, vehicle modifications, and non-medical professional care. Annual costs for each patient were obtained by dividing the total non-medical costs over the patient's life by the number of years the patient was affected. Again, the mean cost was highest for the SMA Early Onset group at $51,665, but these costs varied significantly between patients and the sample size was again small (standard error = $39,501, n = 17). The majority of these funds were used to pay professional caregivers. Patients in the SMA Other group averaged $14,295 for non-medical expenses (standard error = $1651), which was similar to the costs incurred by the other muscular diseases [108, 109] .
Finally, the Lewin group estimated total national cost of illness in the United States for each disease by multiplying the per capita medical expense by three estimations of disease prevalence in the country. Using the moderate estimations for disease prevalence, this yields a total medical cost of $684 million annually for early-onset SMA and $273 million for SMA with an onset of later than three years [108, 109] . Since SMA occurs at a similar rate across ethnicities [110] , these costs can be expected to be proportionately similar in other countries, although costs of medical services will vary by country. Obviously, the significant medical and supportive costs incurred in caring for patients with SMA underscore the need for effective therapeutics and early intervention.
Cost effectiveness of SMA screening
In order to assess the cost effectiveness of prenatal SMA screening, Little et al. developed a theoretical model comparing universal screening to complete absence of screening using values derived from literature [102] . This study took into account expenses such as carrier testing, amniocentesis, fetal testing, and pregnancy termination in instances of a positive fetal test, versus the total lifetime cost of caring for a child with severe or mild disease. The authors also took into account maternal quality-adjusted life years (QALYs), a measure of disease burden on quality of life lived. Little et al. estimated the total cost of universal screening to be $44 million per 100,000 women, or approximately $5 million per SMA case averted. In contrast, the total cost for treating the 10 affected children (per 100,000 women) predicted to be born in the absence of screening would be about $4.7 million. The authors ultimately concluded that universal prenatal screening was not cost effective; however, their study suggested that for populations at high risk, such as those with a family history of SMA, carrier testing may still be a cost-effective strategy.
Final perspective
Spinal muscular atrophy can cause tremendous sufferingphysical, financial, and emotional -to the patient and the family of the affected individual. Currently, from an economic perspective, universal testing for SMA does not appear a viable choice. However, testing of individuals at high risk, such as those with a family history of SMA, is prudent. A positive result from carrier screening in parents can lead to prenatal screening of the child. An unborn child confirmed to have homozygous deletion or mutation in SMN1 can be tested for SMN2 gene dosage. Although SMN2 gene dosage is not a perfect predictor of SMA disease type, given proper counseling and support, the family of an affected child could consider the probability of their child being born with severe disease and tailor their response accordingly. This information would assist the parents in making an informed decision in the unfortunate event that the prognosis for their unborn child is extremely poor, or make appropriate preparations, both practically and emotionally, for a child whose life expectancy is normal, but will require additional attendance and assistance with mobility.
SMA currently has no effective treatment or cure, but several experimental therapeutics have reached advanced stage of clinical testing in human patients. All available data from studies in animal models of SMA have suggested that maximum benefit is achieved only when the therapy is initiated prior to overt loss of motor neurons. It is logical to assume that the same will occur in human patients, indicating that early detection of SMA is desirable either to initiate therapy very soon after birth, or perhaps even in utero in the case of a child with severe SMA. Prenatal screening will identify affected children before the closure of the therapeutic window, allowing these patients to be treated with emerging SMA therapeutics.
Any argument for or against prenatal or neonatal screening for SMA that is based solely on economics has not taken into account the very legitimate issues of parent preparedness and potential for early therapeutic intervention. As technology progresses, and the cost of screening for SMA becomes less and new therapeutics become available, it will be important to readdress the need for SMA screening. Although SMA is presently incurable, prenatal or neonatal screening will be a boon to quality of life for patients and a crucial catalyst for the development of treatments and possibly a cure.
